MD-711 Phase 2/3 Study in PAH

MD-711 Phase 2/3 Study in Pulmonary Arterial Hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224582

Enrollment

Registered

2019-03-05

Start date

2019-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension

Interventions

investigational material(s) Generic name etc : MD-711 INN of investigational material : treprostinil Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Group 1 under the updated clinical classification of pulmonary hypertension (5th World Symposium on Pulmonary Hypertension in Nice 2013)

Exclusion criteria

Exclusion criteria: Patients who have any of the diseases which are included in the Groups 2 to 5 under the updated clinical classification of pulmonary hypertension

Design outcomes

Primary

Measure	Time frame
efficacy Rate of change in PVRI	—

Secondary

Measure	Time frame
safety efficacy pharmacokinetics - Efficacy Change in 6-minute walk distance - Safety Adverse Reactions - Pharmacokinetics Plasma levels of treprostinil	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026